Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to expand public awareness campaigns for prostate cancer, following the prediction by the Lancet Commission of a surge in cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to recent research conducted by the Lancet Commission, what steps they plan to take to address the projected surge in prostate cancer cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Siobhan Baillie (Conservative - Stroud)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to The Hughes Report, published by the Patient Safety Commissioner on 7 February 2024, if she will ensure that people impacted by bowel mesh are eligible for financial redress.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations and will respond substantively in due course. Bowel mesh, also known as rectopexy mesh, did not fall within the definition of pelvic organ prolapse that the PSC investigated for her report.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many emergency hospital admissions there have been following falls by patients aged 65 and over in each financial year since 2010-11.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
NHS England publishes information on finished consultant episodes (FCEs) for admitted patients, which is available at the following link:
The following table shows the total number of FCEs relating to a fall, where the patient was 65 years old or over, each year from 2012/13, the earliest year from which data is available, to 2022/23:
Year | FCEs relating to a fall |
2012/13 | 283,794 |
2013/14 | 290,381 |
2014/15 | 304,049 |
2015/16 | 312,476 |
2016/17 | 316,647 |
2017/18 | 334,986 |
2018/19 | 345,494 |
2019/20 | 360,677 |
2020/21 | 334,418 |
2021/22 | 350,545 |
2022/23 | 339,928 |
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NICE guidance entitled Integrated health and social care for people experiencing homelessness, published on 16 March 2022, what steps her Department is taking to ensure that people experiencing homelessness have somewhere safe and secure to recover when discharged from hospital.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department is committed to promoting safe and timely discharge for people experiencing, or at risk of, homelessness, to appropriate accommodation.
We have ensured every acute hospital has access to a care transfer hub to manage discharge for people with more complex needs. In January 2024, the Department published guidance on discharging people at risk of or experiencing homelessness, to support staff involved in planning safe and supportive discharge of these patients from hospital. The guidance is available at the following link:
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what plans they have to use artificial intelligence systems to support the diagnosis of prostate cancer, as recommended by the Lancet Commission in research published on 4 April.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the Lancet Commission on prostate cancer, published 4 April 2024.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Mike Amesbury (Labour - Weaver Vale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the implications for her policies of the independent report by Carlo Breen into the Northern Care Alliance NHS Foundation Trust’s historic management of concerns in relation to a Consultant Spinal Surgeon, published on 7 March 2024.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Northern Care Alliance NHS Foundation Trust commissioned the Spinal Patient Safety Look Back review in 2021. A report detailing the findings was published in July 2023. A second report was commissioned by the trust to review the historic management of concerns raised in relation to a particular surgeon. The findings of this report were published on 7 March 2024, and relate to issues that include bullying, speaking up, the duty of candour, governance, and the quality of disciplinary investigations at the trust.
The Government is already taking action in relation to policies relevant to the report’s findings. This includes strengthening leadership, the statutory duty of candour, and speaking up to promote an open and transparent learning culture in the National Health Service. We also expect NHS organisations to have robust policies in place to tackle bullying and harassment.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of capacity in district nursing on the timeliness of patient discharge from hospital in 2023.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Virendra Sharma (Labour - Ealing, Southall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure that (a) young and (b) vulnerable people have access to free contraception.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.